Glaukos, Attillaps enter licensing agreement for Demodex-targeting therapies
Glaukos and Attillaps Holdings have entered into a licensing agreement that grants Glaukos a global exclusive license to Attillaps’ library of proprietary investigational compounds targeting Demodex mites, according to a press release.
The agreement grants Glaukos exclusive right to develop, manufacture and commercialize products using acetylcholinesterase inhibitors to treat Demodex-related ophthalmic diseases.
“This licensing agreement adds a promising therapeutic class that expands the focus of our emerging corneal health franchise into new and globally underserved disease indications,” Thomas Burns, Glaukos president and CEO, said in the release. “Attillaps’ proprietary compounds and targeted ophthalmic indications are highly complementary to our expanding portfolio of sustained pharmaceuticals and represent a synergistic fit with our ongoing corneal health R&D initiatives.”
The companies did not disclose financial terms of the agreement.